Your browser doesn't support javascript.
loading
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
Zoeller, Jason J; Press, Michael F; Selfors, Laura M; Dering, Judy; Slamon, Dennis J; Hurvitz, Sara A; Brugge, Joan S.
Afiliação
  • Zoeller JJ; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Press MF; Pathology, University of Southern California, Los Angeles, California, United States of America.
  • Selfors LM; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Dering J; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, United States of America.
  • Slamon DJ; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, United States of America.
  • Hurvitz SA; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, United States of America.
  • Brugge JS; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One ; 16(5): e0251163, 2021.
Article em En | MEDLINE | ID: mdl-33951110
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article